P. Bonetti

发表

Treatment of chronic hepatitis C with recombinant human interferon‐α2a: Results of a randomized controlled clinical trial

M. Rugge, G. Realdi, A. Tagger, 1994 .

Randomized trial comparing three different regimens of alpha‐2a‐interferon in chronic hepatitis C

A. Alberti, P. Pontisso, F. Noventa, 1995 .

Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. The TriVeneto Viral Hepatitis Group.

P. Pontisso, F. Noventa, L. Chemello, 1995, Hepatology.

Antibody to hepatitis C virus in cryptogenic chronic liver disease

A. Alberti, G. Realdi, A. Ruol, 1991, Journal of medical virology.

Relationship between serum HCV markers and response to interferon therapy in chronic hepatitis C

G. Realdi, A. Ruol, M. Fasola, 1994, Digestive Diseases and Sciences.

Treatment with interferon(s) of community-acquired chronic hepatitis and cirrhosis type C. The TVVH Study Group.

A. Alberti, C. Casarin, L. Chemello, 1993, Journal of hepatology.

Interferon therapy of cryptogenic chronic active liver disease and its relationship to anti-HCV.

A. Alberti, G. Realdi, A. Ruol, 1992, Archives of virology. Supplementum.

Predictors of sustained response, relapse and no response in patients with chronic hepatitis C treated with interferon‐α

A. Alberti, P. Pontisso, F. Noventa, 1995, Journal of viral hepatitis.

Treatment of chronic hepatitis C with recombinant human interferon-alpha 2a: results of a randomized controlled clinical trial.

M. Rugge, A. Tagger, F. Noventa, 1994, Hepatology.

Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients.

A. Bhalla, H. Thomas, F. Nevens, 1997, Gastroenterology.

Distribution of three major hepatitis C virus genotypes in Italy. A multicentre study of 49 5 patients with chronic hepatitis C

F. Negro, A. Alberti, P. Pontisso, 1995, Journal of viral hepatitis.

TREATMENT OF CHRONIC HEPATITIS C WITH DIFFERENT REGIMENS OF INTERFERON ALPHA-2a (IFN-2a)

A. Alberti, P. Pontisso, L. Chemello, 1993 .

Recombinant human interferon alfa-2a in community-acquired non-A, non-B chronic active hepatitis. Preliminary results of a randomized, controlled trial.

A. Alberti, G. Realdi, A. Ruol, 1990, Journal of hepatology.

Persistent Hepatitis C Viremia Predicts Late Relapse after Sustained Response to Interferon- in Chronic Hepatitis C

A. Alberti, P. Pontisso, C. Casarin, 1996, Annals of Internal Medicine.

Interferon antibodies in patients with chronic hepatitic C virus infection treated with recombinant interferon alpha-2 alpha.

A. Alberti, G. Realdi, A. Ruol, 1994, Journal of hepatology.

Treatment of chronic hepatitis C with interferon‐α by monitoring the response according to viraemia

A. Alberti, P. Pontisso, C. Antona, 1997, Journal of viral hepatitis.

Cryptogenic chronic liver disease and serum or liver hepatitis B virus markers. Their possible correlations and etiologic significance.

A. Alberti, G. Realdi, P. Pontisso, 1988, Digestion.

Persistent hepatitis C viremia predicts late relapse after sustained response to interferon-alpha in chronic hepatitis C. TriVeneto Viral Hepatitis Group.

A. Alberti, P. Pontisso, C. Casarin, 1996, Annals of internal medicine.

Prevalence of Helicobacter pylori infection in elderly inpatients and in institutionalized old people: correlation with nutritional status.

A. Baldassarri, M. Monti, E. Cunietti, 1996, Age and ageing.

Serum alanine aminotransferase levels among volunteer blood donors: effect of sex, alcohol intake and obesity.

G. Realdi, N. Bizzaro, F. Noventa, 1992, The Italian journal of gastroenterology.

Efficacy of a second cycle of interferon therapy in patients with chronic hepatitis C.

P. Pontisso, L. Chemello, L. Cavalletto, 1997, Gastroenterology.

Cryptogenic chronic active liver disease. Evaluation of serum aminoterminal peptide of type III procollagen as a marker of histological activity

M. Rugge, G. Realdi, M. Plebani, 1990, La Ricerca in clinica e in laboratorio.